Ajanta Pharma Limited — Q3 FY26
Ajanta Pharma delivered a strong Q3 FY26 with consolidated revenue of ₹1,375 crore (+20% YoY) and EBITDA of ₹382 crore (+19% YoY), driven by robust US generics (+52% YoY) and In...
bullish
high
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q2 FY26
EBITDA margin guidance of 27% ±1% for H2 FY26
Management reiterated EBITDA margin guidance of 27% ±1% for the remaining two quarters, excluding forex mark-to-market impact.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
US generics growth to sustain at current run-rate
Management expects US generics to maintain the current quarterly run-rate of ~₹343 crore for the next two quarters.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
Africa business upgraded to double-digit growth for FY26
Management upgraded Africa growth guidance from mid-single-digit to double-digit for the full year, citing favorable base effect.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1
Q2 FY26
Capex guidance of ₹300 crore for FY26
Capex incurred ₹145 crore in H1; full-year capex expected to be ₹300 crore as guided earlier.
Missed
Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.
heuristic_v1